Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Recruiting 10Terminated 2Active not recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Dermatologic 1

Conditions

Prostatic Neoplasms 19Breast Neoplasms 12Lung Neoplasms 10Brain Neoplasms 9Glioblastoma 7Neoplasm Metastasis 6Neoplasms 5Glioma 5Carcinoma, Renal Cell 5Carcinoma, Non-Small-Cell Lung 5Sarcoma 4Pancreatic Neoplasms 4Head and Neck Neoplasms 4Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Mycosis Fungoides 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell, Marginal Zone 3Liver Neoplasms 3Gliosarcoma 3Waldenstrom Macroglobulinemia 2Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Sezary Syndrome 2Rectal Neoplasms 2Ovarian Neoplasms 2Oligodendroglioma 2Neuroendocrine Tumors 2

Interventions

Rituximab 58Cyclophosphamide 40fludarabine phosphate 27fludarabine 21Lenalidomide 19Mycophenolic Acid 17idelalisib 16Antilymphocyte Serum 16Cyclosporine 15Tacrolimus 13Radiotherapy 13Filgrastim 13venetoclax 12umbralisib 12Whole-Body Irradiation 12Busulfan 12Bendamustine Hydrochloride 12ublituximab 11ibrutinib 11Methotrexate 11Peripheral Blood Stem Cell Transplantation 10Alemtuzumab 10obinutuzumab 9Melphalan 9Chlorambucil 8Bortezomib 8thymoglobulin 7ofatumumab 7Etoposide 7Clofarabine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Leukemia, Lymphocytic, Chronic, B-Cell × Magnetic Resonance Spectroscopy × Clear all
NCT06343376 2025-08-03

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Roswell Park Cancer Institute

Phase 1 Terminated
1 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT00504205 2013-08-02

MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma

National Cancer Institute (NCI)

Phase NA Terminated
30 enrolled
DermatologicLymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡